FIELD: medicine; pharmaceuticals.
SUBSTANCE: invention provides an agent for treatment and prevention of neurodegenerative diseases and vascular dementia, comprising at least one lithium salt selected from lithium pyroglutamate, lithium thyrosinate, lithium argininate, lithium pyruvate, lithium lysinate, lithium malate, lithium alaninate, lithium lactate, lithium cysteinate, lithium tryptophanate, lithium aspartate, lithium benzoate, lithium adipate, lithium glycinate, lithium gluconate, lithium citrate, lithium nicotinate, lithium orotate, lithium salicylate and vitamin D in form of cholecalciferol or biologically active neurotrophic peptide selected from: glycine-glutamate-phenylalanine-serin-valine, tyrosine-glycine-glycine-phenylalanine-leucine, tyrosine-glycine-glycine-phenylalanine-methionine, cysteine-cysteine-arginine-glutamine-lysine, tryptophan-tryptophan-leucine-asparagine-serine-alanine-glycine-tyrosine.
EFFECT: invention provides higher bioavailability for neurons, as well as safe treatment and prevention of using low doses of active substance.
10 cl, 10 ex, 1 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD FOR PREVENTING AND TREATING NEURODEGENERATIVE PATHOLOGY AND VASCULAR DEMENTIA | 2014 |
|
RU2587617C1 |
| LITHIUM-CONTAINING AGENT TO PREVENT AND TREAT CEREBROVASCULAR DISEASES AND METHOD OF APPLICATION THEREOF | 2008 |
|
RU2367427C1 |
| NEUROPROTECTIVE AGENT | 2016 |
|
RU2614697C1 |
| METHOD FOR NON-INVASIVE ASSESSMENT OF THE AVERAGE LEVEL OF NEUROTROPHIC FACTOR OF BRAIN (BDNF) IN BLOOD PLASMA BASED ON INDICATORS OF MICROELEMENT HAIR ANALYSIS | 2017 |
|
RU2671636C1 |
| POLYVITAMIN KIT FOR WOMEN | 2010 |
|
RU2443422C2 |
| METHOD FOR PREDICTION OF PROGRESSION OF BREAST CANCER | 2020 |
|
RU2741232C1 |
| APPLICATION OF LITHIUM ASCORBATE FOR PREVENTION AND TREATMENT OF CHRONIC ALCOHOLIC INTOXICATION | 2017 |
|
RU2639496C1 |
| METHOD FOR CHOOSING A THERAPEUTIC DOSE OF CHOLECALCIFEROL FOR A PATIENT WITH INSUFFICIENT PROVISION OR VITAMIN D DEFICIENCY WHO HAS UNDERGONE BREAST CANCER | 2021 |
|
RU2762772C1 |
| SYGETHIN-BASED PHARMACEUTICAL STRUCTURE FOR OSTEOPOROSIS PREVENTION AND TREATMENT (VERSIONS) | 2007 |
|
RU2356546C1 |
| PHARMACEUTICAL COMPOSITION FOR PREVENTION AND TREATMENT OF MENOPAUSE OSTEOPOROSIS IN WOMEN | 2007 |
|
RU2379043C2 |
